Single and repeated doses of egb 761 do not affect pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects

HIGHLIGHTS

• who: Ginkgo biloba extract and collaborators from the Willmar Schwabe GmbH and CoKG, Clinical Research, Karlsruhe, Germany Takasaki University of Health and have published the research work: Single and Repeated Doses of EGb 761 do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects, in the Journal: (JOURNAL)

SUMMARY

Frontiers in Pharmacology | www.frontiersin.org April 2022 | Volume 13 | Article 868843 Hoerr et_al Interaction Study of EGb 761 with Rivaroxaban Frontiers in Pharmacology | www.frontiersin.org Participants Healthy Caucasian males or females of at least 18 years of age, with a body . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.